Mechanism of action of pimavanserin in Parkinson's disease psychosis: targeting serotonin 5HT2A and 5HT2C receptors.

Article Details

Citation

Copy to clipboard

Stahl SM

Mechanism of action of pimavanserin in Parkinson's disease psychosis: targeting serotonin 5HT2A and 5HT2C receptors.

CNS Spectr. 2016 Aug;21(4):271-5. doi: 10.1017/S1092852916000407.

PubMed ID

27503570 [ View in PubMed

]

Abstract

Pimavanserin, a novel agent approved for the treatment of Parkinson's disease psychosis, has potent actions as an antagonist/inverse agonist at serotonin 5HT2A receptors and less potent antagonist/inverse agonist actions at 5HT2C receptors.

DrugBank Data that Cites this Article

Drugs

Pimavanserin

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Pimavanserin	5-hydroxytryptamine receptor 2C	Protein	Humans	Unknown	Inverse agonist	Details